Ankylosing Spondylitis Treatment Market – By Drug Class , By Treatment Approach , By Stage of Disease and By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030.

Ankylosing Spondylitis Treatment Market Overview

Ankylosing Spondylitis Treatment market size is forecast to reach US$10.3 billion by 2030, after growing at a CAGR of 8.8% during 2024-2030. Ankylosing Spondylitis treatment focuses on managing pain and inflammation through medications (such as NSAIDs, biologics, and JAK inhibitors), physical therapy to maintain mobility and strength, lifestyle changes, and in severe cases, surgery to prevent joint damage and improve quality of life. The drivers for the Ankylosing Spondylitis treatment market include the rising prevalence of AS, advancements in biologics and biosimilars, expanding treatment options, increasing healthcare expenditure, a growing geriatric population, patient awareness, improved diagnostic capabilities, R&D investments, supportive regulatory frameworks and the rise of digital health and telemedicine.The increasing use of TNF inhibitors and IL-17 inhibitors, as well as the development of newer biologics, are transforming the treatment landscape by offering more effective and targeted options for managing AS. The rise of biosimilars, which are more cost-effective alternatives to original biologics, is expanding access to treatment and driving market growth, particularly in emerging economies. In December 2023, Biocon Biologics Ltd signed a distribution agreement with Sandoz, granting the company the exclusive rights to promote, sell and distribute Adalimumab BS injection in Japan. Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira and is indicated for rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease and ulcerative colitis. 

Ankylosing Spondylitis Treatment Market - Report Coverage:

The “Ankylosing Spondylitis Treatment Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Ankylosing Spondylitis Treatment Market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

• The COVID-19 pandemic disrupted the Ankylosing Spondylitis (AS) treatment market by delaying diagnosis, treatment initiation and clinical trials due to overwhelmed healthcare systems. Due to the focus on containing the spread of infection, immunocompromised individuals were advised to stay home. Supply chain disruptions also impacted the availability of essential drugs like TNF inhibitors. Clinical trials for new AS therapies faced significant delays, though some adapted to virtual platforms. 
• The Ukraine war severely impacted the AS treatment market by displacing patients and straining healthcare systems. The war disrupted pharmaceutical supply chains, leading to shortages and delays in the delivery of biologic drugs. Additionally, the conflict caused economic instability, which led to higher drug prices and further limited access to treatments, particularly in Europe.

Key Takeaways

NSAIDs are the Largest Segment

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are the largest segment in the ankylosing spondylitis (AS) treatment market due to their effectiveness in reducing pain and inflammation. They serve as the first-line therapy for many patients, providing an affordable and accessible treatment option. The market for NSAIDs is also boosted by the development of new formulations with improved efficacy and fewer side effects. Major pharmaceutical companies like AbbVie, Pfizer, and Merck & Co. are key players in this space. Overall, the NSAID segment remains dominant in the ankylosing spondylitis treatment market, with its market share expected to sustain due to continuous advancements and the growing need for effective pain management solutions. In Estonia, the most purchased over-the-counter medicines in 2023 were those containing paracetamol and ibuprofen, according to data from Benu pharmacy chain. Prescription drugs made up 87% of sales as per statistics from the State Agency of Medicines (Raviamet). As NSAIDs are easier to obtain as they, these drugs hold the largest market share and are anticipated to continue their dominance over the forecast period.

Pharmacological Treatment the Largest Segment

Pharmacological treatments are the most common and widely adopted method for managing ankylosing spondylitis (AS). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically the first line of treatment, offering relief from inflammation and pain. For patients with more severe symptoms, disease-modifying antirheumatic drugs (DMARDs) and biologics are prescribed to slow disease progression and improve mobility. In March 2023, Enzene Biosciences, a subsidiary of Alkem Laboratories, one of the top five pharmaceutical companies in India, announced the commercial release of its biosimilar for Adalimumab, a drug used to treat Ankylosing spondylitis and rheumatoid arthritis. The ease of administration, accessibility, and well-established efficacy of pharmacological options contribute to their dominance. Moreover, advancements in drug formulations and delivery systems continue to enhance patient outcomes, reinforcing their leading position.

North America Dominates the Market

The U.S. has one of the highest incidences of autoimmune and inflammatory diseases, and AS is no exception. As awareness about AS increases and more patients are diagnosed early, there is a growing demand for effective therapies, especially biologics like TNF inhibitors (e.g., Humira, Enbrel) and IL-17 inhibitors (e.g., Cosentyx). The U.S. market benefits from well-established healthcare systems that provide easy access to these treatments, including insurance coverage that supports the high cost of biologic drugs. The country's advanced medical infrastructure, including specialized rheumatology clinics and research institutions, further drives the growth of the AS treatment market. Moreover, ongoing innovations and the launch of new biologic therapies continue to fuel the market in North America. In September, 2024, the FDA approved BIMZELX® (bimekizumab-bkzx) for psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS), making it the first U.S. treatment targeting IL-17A and IL-17F for four inflammatory diseases, including plaque psoriasis. Phase 3 trials showed rapid, sustained improvements in symptoms across patient groups. Administered as a 160 mg injection every four weeks, BIMZELX provides a new, effective treatment option for chronic inflammatory diseases. On January 3, 2025, Pfizer announced FDA approval of XELJANZ®/XELJANZ® XR (tofacitinib) for adults with active ankylosing spondylitis (AS) who do not respond to or tolerate TNF blockers. 

Increasing Prevalence of Ankylosing Spondylitis Drives the Market

AS is a chronic inflammatory disease that can cause debilitating symptoms and permanent joint damage if left untreated, so early diagnosis is critical to managing the disease. The increasing prevalence of Ankylosing Spondylitis (AS) worldwide is one of the most significant drivers of the AS treatment market. According to the World Health Organization website, the prevalence of Ankylosing spondylitis varies by region: per 10 000 people, it is 23.8 in Europe, 16.7 in Asia, 31.9 in North America, 10.2 in Latin America, and 7.4 in Africa. Cases of Ankylosing spondylitis (as other musculoskeletal disorders) are predicted to have an increase of at least 50% between 2020 to 2050. As awareness about AS improves among both the general population and healthcare professionals, more patients are being diagnosed earlier, which has led to a greater demand for effective treatment options. With the growing recognition of the importance of early intervention and the development of advanced biologic therapies, such as TNF inhibitors and IL-17 inhibitors, there is a surge in demand for these treatments. 

High Cost of Biotherapies to Hamper the Market

Biologic drugs, such as TNF inhibitors and IL-17 inhibitors, are highly effective in managing AS but come with significant costs, which can limit patient access, especially in low- and middle-income countries. Although these therapies are often covered by insurance in high-income regions, the out-of-pocket expenses for patients can still be substantial. This challenge is compounded by the growing financial burden on healthcare systems, which must balance the cost of advanced treatments with broader public health needs. The high cost of biologics also drives the market for biosimilars, but even these alternatives, while more affordable, may still be inaccessible to some patients. As a result, ensuring widespread access to effective treatments remains a critical issue for the AS treatment market.

For more details on this report - Request for Sample

Key Market Players

Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Ankylosing Spondylitis Treatment Market. The top 10 companies in this Ankylosing Spondylitis Treatment market are listed below:

1. AbbVie Inc.
2.  Pfizer Inc.
3. Novartis AG
4. Amgen Inc.
5. Sandoz Group AG 
6. AstraZeneca
7. Eli Lilly and Company
8. Bayer AG
9. Biogen Inc.
10. F. Hoffmann La Roche

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here